Hyperandrogenism and menstrual imbalance are the best predictors of metformin response in PCOS patients.

ABSTRACT:

Background

Moving from the correlation between insulin-resistance and PCOS, metformin has been administered in some PCOS women improving ovulatory and metabolic functions and decreasing androgen levels. Inconsistency and unpredictability of response to metformin limit its extensive use. Aim of this study was to identify reliable predictors of response to metformin therapy for weight loss and reduction in plasma androgen levels using ANNs (artificial neural networks).

Methods

One hundred eight consecutive women with PCOS (ESHRE/ASRM 2003 Rotterdam criteria) treated with metformin 1500 mg/day, at inclusion and every 6 months underwent to a complete clinical, endocrine/metabolic assessment and ultrasonographic evaluation. Therapy outcomes were BMI reduction (≥1 kg/m²

SUBMITTER: Garzia E 

PROVIDER: S-EPMC8729102 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature